VXRT - What To Expect From Vaxart And Its Quest To Develop COVID-19 Candidate
Source: company website
Biotech Vaxart (VXRT) jumped pre-market on April 21 on the news it had achieved positive results in pre-clinical trials concerning work on its oral vaccine candidates for COVID-19.
In this article we'll examine the implications of the progress on the share price of the company going forward, why an oral delivery system could be superior to other vaccine candidates, and what to take into account if considering taking a position in the company.
Before that, we'll look at its most recent earnings report.
Latest earnings
In its last earnings report